瑞舒伐他汀联合依折麦布对早期糖尿病肾病患者的影响

目的 观察瑞舒伐他汀联合依折麦布对早期糖尿病肾病的影响.方法 血糖控制良好的158位糖尿病肾病患者随机分为治疗组和对照组,治疗组在常规治疗基础上加服瑞舒伐他汀和依折麦布各10mg/d；对照组在常规治疗基础上加服瑞舒伐他汀10mg/d.观察两组空腹血糖、餐后2h血糖、总胆固醇、甘油三酯、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇、肌酐、血肌酸激酶、谷丙转氨酶、谷草转氨酶、尿白蛋白排泄率(UAER).结果 两组LDL-C治疗后均下降(P＜0.05),且治疗组较对照组明显(P＜0.01)；治疗组空腹血糖、餐后2h血糖较对照组有改善(P＜0.05)；治疗组UAER较治疗前显著下降(P＜0.01),较对照组下降明显(P＜0.05)；两组酶学及肌酐变化未见明显差异.结论 瑞舒伐他汀联合依折麦布较单用瑞舒伐他汀能更有效地改善早期糖尿病肾病患者的血脂谱、降低UAER、改善空腹血糖及餐后2h血糖水平,且无肝脏、肾脏及肌肉损伤.

Effect of combined rosuvastatin and ezetimibe on early diabetic nephropathy

Objective To observe the effect of combined rosuvastatin and ezetimibe on early diabetic nephropathy(DN).Methods One hundred and fifty-eight DN patients with their blood sugar well controlled were randomly divided into treatment group and control group.Patients in treatment group were given ezetimibe(10mg/d) and rosuvastatin(10mg/d) with the addition of routine treatment and those in control group were given only rosuvastatin(10mg/d) to observe their fasting blood glucose,postprandial 2-h blood glucose,total cholesterol,triglycerides,low density lipoprotein cholesterol(LDL-C),high density lipoprotein cholesterol(HDL-C),creatinine,serum creatine kinase,alanine aminotransferase,aspartate aminotransferase levels,urinary protein excretion rate(UAER) and other biochemical indicators.Results The LDL-C,fasting blood glucose,postprandial 2-h blood glucose levels and UAER were significantly lower in treatment group than in control group after treatment(P<0.05).No significant difference was observed in transaminase and creatinine between the two groups.Conclusion Combined ezetimibe and rosuvastatin can improve the lipid profile and reduce UAER,fasting blood glucose,postprandial 2-h blood glucose levels more effectively than rosuvastatin alone with no damage to liver,kidney and muscle.